Global Dendritic Cell Cancer Vaccine Market Dosage Price & Clinical Trials Outlook 2024 - ResearchAndMarkets.com

DUBLIN--()--The "Global Dendritic Cell Cancer Vaccine Market Dosage Price & Clinical Trials Outlook 2024" report has been added to ResearchAndMarkets.com's offering.

Global Dendritic Cell Cancer Vaccine Market Dosage Price & Clinical Trials Outlook 2024 Report Highlight:

  • Role of Dendritic Cells in Immune System & Cancer
  • Price & Dosage Analysis of Marketed Dendritic Cell Cancer Vaccine
  • Availability & Efficacy Analysis
  • Marketed Dendritic Cell Cancer Vaccines Clinical Insight: 3 Vaccines
  • Comparative Assessment of Provenge v/s other Key Therapeutics
  • Dendritic Cell Cancer Vaccines Clinical Pipeline by Company, Indication & Phase: 63 Vaccines

Dendritic cell cancer vaccines have gained significant importance in the market with the approval of first dendritic cell cancer vaccine for metastatic prostate cancer called Provenge. Provenge was approved almost a decade ago and has generated high revenues for the pharmaceutical companies. Dendritic cell vaccines became one of the most promising approaches as it works by boosting up the immune system which in turn will cause no or minimal side effects. Furthermore, cancer is disease with multiple causes and risk factors; researchers stated that instead of preventive vaccines, effective therapeutic vaccines can be developed to treat cancer.

Followed by the approval of Provenge, several similar products were developed for other indications in different regions of the world including CreaVax in South Korea for prostate and kidney cancer and Apceden in India for multiple solid tumors. Additionally, a wide range of dendritic cell vaccines entered in different phases of clinical pipeline such as Vaccell in Japan, TAP Cells in Chile, MelCancerVac in North America and Rocapuldencel-T in US, etc. All these dendritic cell cancer vaccines are expected to be approved and commercialized and enhance the Global Dendritic cell vaccine market.

Dendritic cell vaccine is the fastest growing segment of cancer vaccine market with other classes of vaccine like peptide vaccines, HPV vaccine, HBV vaccines, etc. Dendritic cell vaccines are more specific for treating cancer while others are limited to the treatment of chronic conditions which can cause cancer. Additionally, development of dendritic cell vaccine has been one of the fastest growing sectors amongst all and has resulted in a strong clinical pipeline with more than 60 products in different phases of clinical trials.

Key Topics Covered:

1. Prologue to Dendritic Cell Cancer Vaccine

2. Role of Dendritic Cells in Immune System & Cancer

3. Mechanism of Action of Dendritic Cell Cancer Vaccines

4. Commercially Approved Dendritic Cell Cancer Vaccine: Efficacy, Availability, Price & Dosage Analysis

5. Marketed Dendritic Cell Cancer Vaccines Clinical Insight

6. Promising Candidates in Dendritic Cell Cancer Vaccine in Clinical Pipeline

7. Comparative Assessment of Provenge v/s other Therapeutics for Prostate Cancer

8. Dendritic Cell Cancer Vaccine Market Opportunity Regional Analysis

9. Dendritic Cell Cancer Vaccine Combination Therapy with other Cancer Therapies

10. Global Dendritic Cell Cancer Vaccine Current Market Overview

11. Promising Future of Dendritic Cell Vaccines in Various Cancer

12. Global Dendritic Cell Cancer Vaccine Market Dynamics

13. Global Dendritic Cell Cancer Vaccine Market Future Forecast

14. Global Dendritic Cell Cancer Vaccines Clinical Pipeline Overview

15. Global Dendritic Cell Cancer Vaccines Clinical Pipeline by Company, Indication & Phase

16. Competitive Landscape

  • 3M Company
  • Activartis
  • Argos Therapeutics
  • Batavia Bioservices
  • Bellicum Pharmaceuticals
  • Creagene
  • DCPrime
  • DanDrit Biotech
  • Dendreon Corporation
  • Elios Therapeutics
  • Glaxo Smith Kline
  • Immunicum
  • ImmunoCellular Therapeutics
  • Kiromic
  • Medigene
  • Merck
  • Northwest Biotherapeutics
  • SOTIO
  • Tella Incorporation
  • Theravectys
  • Vaxil BioTherapeutics

For more information about this report visit https://www.researchandmarkets.com/research/kvrz99/global_dendritic?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials, Cancer Vaccines

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Clinical Trials, Cancer Vaccines